Cancerfrom24/7 Wall St.17 hours agoSELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 DeathsSELLAS Life Sciences Group's stock is influenced by the slow death rate in its Phase 3 REGAL trial for a cancer vaccine.